11C-NS14492 as a novel PET radioligand for imaging cerebral α7 nicotinic acetylcholine receptors: In vivo evaluation and drug occupancy measurements

Journal of Nuclear Medicine

Volumn 52, Issue 9, 2011, Pages 1449-1456

  Ettrup, Anders ^a   Mikkelsen, Jens D ^a,b   Lehel, Szabolcs ^a   Madsen, Jacob ^a   Nielsen, Elsebet Ø ^b   Palner, Mikael ^a   Timmermann, Daniel B ^b   Peters, Dan ^b   Knudsen, Gitte M ^a  

^a Rigshospitalet   (Denmark)

^b NEUROSEARCH A S   (Denmark)

Author keywords

Nicotinic acetylcholine receptors; Novel tracer; Occupancy plot; Porcine; Positron emission tomography

Indexed keywords

1,4 DIAZABICYCLO[3.2.2]NONANE 4 CARBOXYLIC ACID 4 BROMOPHENYL ESTER; BUNGAROTOXIN RECEPTOR; CARBON 11; METHYL TRIFLATE C 11; NICOTINIC AGENT; NS 14492; NS 14492 C 11; RADIOPHARMACEUTICAL AGENT; TRIFLUOROMETHANESULFONIC ACID; UNCLASSIFIED DRUG; 4 (5 (1 METHYL 1H PYRROL 2 YL) 1,3,4 OXADIAZOL 2 YL) 1,4 DIAZABICYCLO(3.2.2)NONANE; 4-(5-(1-METHYL-1H-PYRROL-2-YL)-1,3,4-OXADIAZOL-2-YL)-1,4-DIAZABICYCLO(3.2.2)NONANE; ALKALOID; AZABICYCLO DERIVATIVE; AZOCINE DERIVATIVE; CYTISINE; DIAGNOSTIC AGENT; FUSED HETEROCYCLIC RINGS; NICOTINIC RECEPTOR; OXADIAZOLE DERIVATIVE; QUINOLIZINE DERIVATIVE;

ANIMAL EXPERIMENT; ARTERIAL BLOOD; ARTICLE; BRAIN; BRAIN CORTEX; CONTROLLED STUDY; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG UPTAKE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; ISOTOPE LABELING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR OCCUPANCY; SWINE; THALAMUS; ANIMAL; METABOLISM; RADIATION RESPONSE; RAT; TISSUE DISTRIBUTION;

ALKALOIDS; ANIMALS; AZABICYCLO COMPOUNDS; AZOCINES; BICYCLO COMPOUNDS, HETEROCYCLIC; BRAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; OXADIAZOLES; POSITRON-EMISSION TOMOGRAPHY; QUINOLIZINES; RADIOPHARMACEUTICALS; RATS; RECEPTORS, NICOTINIC; SWINE; TISSUE DISTRIBUTION;

EID: 80052634393     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.088815     Document Type: Article

References (31)

1. Freedman R, Olincy A, Buchanan RW, et al. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry. 2008;165:1040-1047.
2. Thomsen MS, Hansen HH, Timmerman DB, Mikkelsen JD. Cognitive improvement by activation of alpha7 nicotinic acetylcholine receptors: from animal models to human pathophysiology. Curr Pharm Des. 2010;16:323-343.
3. Pichat P, Bergis OE, Terranova JP, et al. SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia. Neuropsychopharmacology. 2007;32:17-34. (Pubitemid 44967781)
4. Gee AD. Neuropharmacology and drug development. Br Med Bull. 2003;65:169-177. (Pubitemid 36406465)
5. Lee CM, Farde L. Using positron emission tomography to facilitate CNS drug development. Trends Pharmacol Sci. 2006;27:310-316. (Pubitemid 43870125)
6. Christensen DZ, Mikkelsen JD, Hansen HH, Thomsen MS. Repeated administration of alpha7 nicotinic acetylcholine receptor (nAChR) agonists, but not positive allosteric modulators, increases alpha7 nAChR levels in the brain. J Neurochem. 2010;114:1205-1216.
7. 18F]NS10743. Eur J Nucl Med Mol Imaging. 2009;36:791-800.
8. 11C]NS12857 is a novel PET ligand for imaging a7-nicotinic receptors: preliminary data from the pig brain. In: 2009 Neuroscience Meeting Planner. Chicago, IL: Society for Neuroscience; 2009. Available at: http://www.abstractsonline.com/Plan/ ViewAbstract.aspx?sKey=f59161a9-524e-490a-a210-de273ae6e9eb&cKey= 2b78a2e6-4dce-48b5-8d66-7d81b35749f9&mKey5%7b081F7976-E4CD-4F3D-A0AF- E8387992A658%7d. Accessed July 21, 2011.
9. 11C]CHIBA-1001 as a novel PET ligand for alpha7 nicotinic receptors in the brain: a PET study in conscious monkeys. PLoS ONE. 2008;3:e3231.
10. Ogawa M, Nishiyama S, Tsukada H, et al. Synthesis and evaluation of new imaging agent for central nicotinic acetylcholine receptor alpha7 subtype. Nucl Med Biol. 2010;37:347-355.
11. 11C]CHIBA-1001 for mapping alpha7 nicotinic receptors by positron emission tomography. Ann Nucl Med. 2009;23:301-309.
12. 11C]A-844606 in mice and conscious monkeys. PLoS ONE. 2010;5:e8961.
13. Biton B, Bergis OE, Galli F, et al. SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (1) binding and functional profile. Neuropsychopharmacology. 2007;32:1-16. (Pubitemid 44967780)
14. Briggs CA, Gronlien JH, Curzon P, et al. Role of channel activation in cognitive enhancement mediated by alpha7 nicotinic acetylcholine receptors. Br J Pharmacol. 2009;158:1486-1494.
15. 125I]-alpha- bungarotoxin binding in human postmortem brain. J Comp Neurol. 1997;387:385-398.
16. Koziorowski J, Larsen P, Gillings N. A quartz-lined carbon-11 target: striving for increased yield and specific activity. Nucl Med Biol. 2010;37:943-948.
17. 11C]methyl triflate. Int J Rad Appl Instrum [A]. 1992;43:1383-1385.
18. 11C]methane. Appl Radiat Isot. 1997;48:153-157.
19. Andreasen JT, Andersen KK, Nielsen EO, Mathiasen L, Mirza NR. Nicotine and clozapine selectively reverse a PCP-induced deficit of PPI in BALB/cByJ but not NMRI mice: comparison with risperidone. Behav Brain Res. 2006;167:118-127. (Pubitemid 43063146)
20. Lukas RJ. Interactions of anti-nicotinic acetylcholine receptor antibodies at alpha-bungarotoxin binding sites across species and tissues. Brain Res. 1986;387:119-125. (Pubitemid 17177576)
21. Nielsen SF, Nielsen EO, Olsen GM, Liljefors T, Peters D. Novel potent ligands for the central nicotinic acetylcholine receptor: synthesis, receptor binding, and 3D-QSAR analysis. J Med Chem. 2000;43:2217-2226. (Pubitemid 30354546)
22. 11C]SB207145 in the Gottingen minipig. J Cereb Blood Flow Metab. 2009;29:186-196.
23. Sureau FC, Reader AJ, Comtat C, et al. Impact of image-space resolution modeling for studies with the high-resolution research tomograph. J Nucl Med. 2008;49:1000-1008. (Pubitemid 351793442)
24. Watanabe H, Andersen F, Simonsen CZ, Evans SM, Gjedde A, Cumming P. MR-based statistical atlas of the Gottingen minipig brain. Neuroimage. 2001;14:1089-1096. (Pubitemid 33049850)
25. 11C]-labeled radiopharmaceuticals and their metabolites in plasma. Nucl Med Biol. 2009;36:961-965.
26. 11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab. 1990;10:740-747.
27. Cunningham VJ, Rabiner EA, Slifstein M, Laruelle M, Gunn RN. Measuring drug occupancy in the absence of a reference region: the Lassen plot re-visited. J Cereb Blood Flow Metab. 2010;30:46-50.
28. 123I]epidepride binding to cerebellar dopamine D2/D3 receptors is displaceable: implications for the use of cerebellum as a reference region. Neuroimage. 2007;34:1450-1453.
29. 3H]CHIBA-1001 binding to alpha7 nicotinic acetylcholine receptors in the brain from rat, monkey, and human. Brain Res. 2010;1348:200-208.
30. Kendziorra K, Wolf H, Meyer PM, et al. Decreased cerebral alpha4beta2*nicotinic acetylcholine receptor availability in patients with mild cognitive impairment and Alzheimer's disease assessed with positron emission tomography. Eur J Nucl Med Mol Imaging. 2011;38:515-525.
31. Pinborg LH, Adams KH, Svarer C, et al. Quantification of 5-HT2A receptors in the human brain using [18F]altanserin-PET and the bolus/infusion approach. J Cereb Blood Flow Metab. 2003;23:985-996. (Pubitemid 36959405)